60 mg once daily. HCV genotype 1 or 4 w/o cirrhosis
Daclatasvir + sofosbuvir for 12 wk. Consider prolonging to 24 wk for patients w/ prior treatment including an NS3/4A PI, genotype 1 or 4 w/ compensated cirrhosis
Daclatasvir + sofosbuvir for 24 wk. Consider shortening to 12 wk for previously untreated patients w/ cirrhosis & positive prognostic factors (eg, IL28B CC genotype &/or low baseline viral load), & adding ribavirin for patients w/ very advanced liver disease or w/ other negative prognostic factors (prior treatment experience), genotype 3 w/o cirrhosis
Daclatasvir + sofosbuvir for 12 wk. May be added w/ ribavirin for 24 wk, genotype 4
Daclatasvir for 24 wk in combination w/ peginterferon α + ribavirin for 24-48 wk. If patient has undetectable HCV RNA at both wk 4 & 12, continue all 3 components for a total of 24 wk. If patient achieves undetectable HCV RNA but not at both wk 4 & 12, discontinue Daclatasvir at 24 wk & continue peginterferon α & ribavirin for a total of 48 wk. Co-administration w/ strong CYP3A4 inhibitors
30 mg once daily, moderate CYP3A4 inducers
90 mg once daily.